A. Bardelli

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer

The paper measures mutation rates in microsatellite stable colorectal cancers and finds they vary between tumors and increase during metastasis.

DCs targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

The paper shows that DC-based therapy enhances CD8 T cell responses to neoantigens in lung tumors, particularly in high TMB tumors.

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

This study shows that sorafenib can prolong lung cancer response to EGFR inhibitors by targeting resistant cells' selective advantage.

Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

This study identifies Bcl-xL as a mediator of resistance to KRASG12C inhibitors in colorectal cancer and shows that combining Bcl-xL inhibition with KRASG12C inhibition enhances apoptosis and reduces tumor growth.

Drug-induced colorectal cancer persister cells show increased mutation rate

The paper shows that drug treatment induces colorectal cancer persister cells with significantly increased mutation rates, suggesting new strategies to prevent tumor recurrence.

Evolving neoantigen profiles in colorectal cancers with DNA repair defects

This study tracks neoantigen profiles in colorectal cancers with DNA repair defects, finding dynamic patterns linked to antigen presentation downregulation and evolvability.